Ligand Pharmaceuticals Inc (LGND)
110.58
+0.27
(+0.24%)
USD |
NASDAQ |
Jan 08, 16:00
113.90
+3.32
(+3.00%)
After-Hours: 04:31
Ligand Pharmaceuticals SG&A Expense (Quarterly): 24.48M for Sept. 30, 2024
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Cellectar Biosciences Inc | 7.834M |
| Revance Therapeutics Inc | 62.22M |
| Zymeworks Inc | 13.90M |
| CNS Pharmaceuticals Inc | 1.384M |
| Celularity Inc | 12.65M |